Kristin Smith

The appellant appealed an order regarding the adequacy of pleadings and whether the respondent was immune from suit.

The Court of Appeal noted that pending judicial review applications in the Divisional Court raised many of the same procedural errors alleged in the pleadings.

The Court adjourned the appeal to await the Divisional Court's decision, as it could impact whether the appellant's pleading could survive based on issue estoppel or res judicata.

The appellant appealed a decision of the Health Services Appeal and Review Board under the Independent Health Facilities Act.

The Divisional Court found that the Board erred in law by asking itself the wrong question, limiting its consideration to whether the Director had the authority to revoke the appellant's licence rather than whether the revocation was a reasonable exercise of discretion.

The court rescinded the Board's decision and remitted the matter back for a re-hearing, noting that the Board's process is a hearing where it may substitute its own opinion for that of the Director.

The applicants, who own and operate pharmacies in Ontario, challenged the validity of provincial regulations that prohibited 'private label' generic drugs from being designated as interchangeable or listed for public reimbursement.

The Divisional Court held that the regulations were ultra vires the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act.

The Court found that the enabling statutes authorized the imposition of conditions, not absolute prohibitions, and that the ban on private label products was extraneous to the legislative purpose of controlling drug costs.

The regulations were declared invalid and of no force and effect.

Apotex Inc. sought judicial review of decisions by the Executive Officer of the Ontario Public Drug Programs refusing to increase the reimbursable pricing of three generic antibiotic drugs.

The applicant argued that the historic pricing exemption should apply to allow price increases and challenged the Executive Officer's reliance on the single source pricing exemption to negotiate a price increase with a competitor.

The Divisional Court dismissed the application, finding that the Executive Officer's interpretation of the legislation and regulations was reasonable and that her actions to ensure a continued supply of the drugs were lawful and in the public interest.